Minimal Residual Disease Testing Market Size, Share, Technology Trends, Clinical Adoption and Forecast, 2026–2035

Minimal Residual Disease Testing Market Size & Forecast 2035

The global minimal residual disease testing market was valued at USD 1.68 billion in 2025 and is projected to reach USD 8.47 billion by 2035, expanding at a CAGR of 17.4% during 2026–2035. Minimal residual disease, also described as measurable residual disease in hematologic malignancies and molecular residual disease in solid tumors, is becoming a decision tool rather than a retrospective research marker. In leukemia, lymphoma and multiple myeloma, MRD results are used to assess response depth, stratify relapse risk and support treatment-duration decisions. In solid tumors, circulating tumor DNA testing is being evaluated for post-surgical risk assessment, adjuvant-treatment selection, therapy-response monitoring and recurrence surveillance.

The market’s commercial structure differs sharply by indication. Blood-cancer testing is anchored by established flow cytometry, PCR and next-generation sequencing workflows, defined clinical timepoints and growing reimbursement. Solid-tumor MRD is expanding faster, but adoption depends on prospective evidence that a ctDNA-guided intervention improves patient outcomes rather than merely predicting recurrence. This evidence gap will shape payer coverage, guideline inclusion and ordering volume through 2035.

North America led global revenue in 2025 due to its clinical-trial concentration, reference-laboratory infrastructure, payer activity and early commercialization of NGS and ctDNA assays. Asia-Pacific is forecast to grow fastest as oncology capacity expands and cancer centers adopt molecular monitoring. Across all regions, sample quality, assay sensitivity, turnaround time, longitudinal comparability and clinical actionability determine whether a platform moves from research use to routine care.

Key Highlights

• The market is forecast to rise from USD 1.68 billion in 2025 to USD 8.47 billion by 2035, adding USD 6.79 billion in annual revenue.
• Testing services captured 63.8% of 2025 revenue as specialized reference laboratories handled complex sequencing, bioinformatics and longitudinal reporting.
• Next-generation sequencing held 42.6% of technology revenue in 2025 and is forecast to grow at 19.2% CAGR.
• Blood cancers represented 78.6% of the 2025 market, reflecting established use in leukemia, lymphoma and multiple myeloma.
• Solid-tumor MRD testing is forecast to grow at 27.1% CAGR, the fastest rate among indications, as ctDNA evidence expands.
• Hospitals and cancer centers generated 44.7% of 2025 revenue, supported by defined testing timepoints and clinical-trial activity.
• North America held 51.8% of global revenue in 2025, while Asia-Pacific is projected to record a 20.8% CAGR.
• Clinical adoption increasingly depends on whether an MRD result triggers a validated treatment action, not sensitivity claims alone.

Market Dynamics

MRD moves into treatment-response and trial endpoints

In hematologic malignancies, MRD status can distinguish deep response from conventional remission and identify patients at elevated relapse risk. Drug developers use MRD endpoints to measure activity sooner than long-term survival outcomes in selected trial settings. Each new therapy protocol that specifies serial testing creates demand across baseline clonotype identification, post-induction assessment, consolidation, maintenance and surveillance.

The commercial value extends beyond test volume. Assay providers that support multinational trials must manage sample logistics, validated protocols, central-laboratory workflows, data transfer and regulatory documentation. This favors companies with biopharma partnerships and standardized cross-site testing, not only high analytical sensitivity.

Solid-tumor ctDNA creates the largest expansion opportunity

Tumor-informed and tissue-free assays can detect molecular evidence of residual disease after surgery or other curative-intent treatment. Positive results often identify patients with sharply higher recurrence risk. The next adoption threshold is interventional utility: health systems and payers need evidence that changing chemotherapy, immunotherapy or surveillance according to MRD status improves outcomes and avoids unnecessary treatment.

Colorectal, breast, lung and bladder cancers are major evidence-generation areas. Serial testing creates recurring revenue, but ordering pathways vary by surgery type, stage, tissue availability and treatment plan. Platforms that integrate results with pathology, treatment and longitudinal clinical data can differentiate beyond a binary positive-or-negative report.

Standardization remains an operational constraint

MRD results depend on sample type, collection timing, cellular input, DNA recovery, sequencing depth, limit of detection and bioinformatics rules. Bone marrow and peripheral blood may produce different sensitivity in the same disease. Flow cytometry performance varies with antibody panels, instrument configuration, analyst expertise and sample viability. Solid-tumor assays differ in whether they require tumor tissue, the number of tracked variants and the use of methylation or other signals.

These differences complicate cross-platform comparisons and treatment thresholds. Laboratories need transparent validation, proficiency testing, stable controls and longitudinal consistency. A patient monitored on one assay may not be directly comparable after switching platforms, making vendor continuity clinically important.

Cost and reimbursement determine routine access

NGS-based MRD testing requires sequencing, bioinformatics, specialist interpretation and repeated sampling. Coverage has expanded in selected indications, but broad reimbursement remains uneven, especially for emerging solid-tumor uses. Community oncology sites may rely on reference-laboratory send-outs because they cannot justify in-house infrastructure. In lower-resource markets, flow cytometry and targeted PCR remain more accessible even where NGS offers deeper sensitivity.

Pre-analytics becomes a competitive layer

At very low disease levels, an assay cannot detect molecules that were not captured during collection and extraction. Larger blood or plasma inputs can improve recovery but raise workload, transfer and consistency challenges. Automation that integrates extraction, concentration and quantification can reduce hands-on variability and support higher-throughput MRD programs. This creates a distinct equipment and consumables opportunity upstream of sequencing or PCR.

Market Scope

Market Segmentation Analysis

By Type

Testing services generated 63.8% of market revenue in 2025, equal to USD 1.07 billion. Service-led demand includes central-laboratory testing for routine care, clinical trials and biopharma development. Reference laboratories offer validated assays, specialist bioinformatics and standardized reports without requiring each hospital to build sequencing infrastructure. The segment is forecast to reach USD 5.59 billion by 2035, supported by recurring serial testing and community-oncology access.

Test kits and associated products accounted for 36.2%, or USD 0.61 billion, in 2025. This segment includes assay reagents, flow panels, controls, sample-preparation products and software used in hospital, academic and commercial laboratories. It is forecast to reach USD 2.88 billion by 2035. Growth will depend on decentralized adoption, regulatory status, compatibility with installed instruments and the ability to reproduce performance across laboratories.

By Technology

Next-generation sequencing led with 42.6% of 2025 revenue, equal to USD 0.72 billion. NGS supports high-sensitivity tracking of immune-receptor clonotypes, somatic variants and circulating tumor DNA. It is forecast to reach USD 4.17 billion by 2035 at 19.2% CAGR. Its commercial advantage is deep sensitivity and multiplexed monitoring; its constraints include cost, turnaround time, tissue requirements for some assays and complex informatics.

Flow cytometry held 28.7%, or USD 0.48 billion, in 2025. It remains embedded in leukemia and myeloma workflows because it can characterize abnormal cell populations rapidly and is available in experienced hematopathology laboratories. The segment is forecast to reach USD 1.94 billion by 2035. Standardized antibody panels and automated analysis can improve cross-site reproducibility, but specimen viability and operator skill remain critical.

PCR-based testing represented 22.9%, or USD 0.38 billion, in 2025. Quantitative and digital PCR are valuable where defined targets such as fusion transcripts or mutations can be tracked. Digital PCR is gaining share through high quantitative precision and lower input requirements for selected markers. Other technologies held 5.8%, including emerging methylation, multiomic and computational approaches.

By Indication

Blood cancers accounted for 78.6% of 2025 revenue, equal to USD 1.32 billion. Acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma and multiple myeloma form the market’s clinical foundation. Testing is often scheduled at defined treatment milestones and can influence transplant, maintenance or treatment-duration decisions. The segment is forecast to reach USD 5.67 billion by 2035.

Within blood cancers, leukemia-related testing represented 35.4% of total market revenue in 2025, multiple myeloma 24.1%, and lymphoma and other hematologic malignancies 19.1%. Multiple myeloma is gaining commercial importance as deeper response categories and MRD endpoints become more prominent in trials and treatment assessment.

Solid tumors held 18.2%, or USD 0.31 billion, in 2025 and are forecast to reach USD 3.41 billion by 2035 at 27.1% CAGR. Colorectal cancer currently has one of the deepest clinical evidence bases, while breast, lung, bladder and other tumors are generating new data. The segment’s value lies in repeated testing after curative-intent treatment, but reimbursement will follow prospective interventional evidence and guideline adoption. Other indications represented 3.2%.

By End User

Hospitals and cancer centers generated 44.7% of 2025 revenue, equal to USD 0.75 billion. Large academic and comprehensive cancer centers manage high volumes of hematologic malignancies, conduct trials and operate molecular pathology or advanced flow laboratories. Their influence extends beyond in-house testing because they define clinical protocols and generate evidence used by community sites.

Diagnostic and reference laboratories accounted for 34.8%, or USD 0.58 billion, in 2025. This segment is forecast to grow at 19.5% CAGR as more oncologists use specialized send-out testing. National sample logistics, payer contracting, electronic ordering and predictable turnaround time are core competitive capabilities.

Research institutes and biopharmaceutical sponsors held 15.6%, or USD 0.26 billion. Demand includes therapy trials, endpoint services, assay development and translational research. Other end users represented 4.9%. Biopharma revenue can be concentrated in fewer high-value contracts and requires regulatory-grade data management across multiple sites.

Regional and Country-Level Analysis

North America

North America generated 51.8% of global revenue in 2025, equal to USD 0.87 billion, and is forecast to reach USD 3.98 billion by 2035. The region leads through commercial reference laboratories, NGS adoption, clinical-trial activity, cancer-center density and payer coverage in selected hematologic and solid-tumor settings.

The United States represented 47% of global revenue and 90.7% of North American revenue in 2025, equal to USD 0.79 billion. It combines FDA-cleared hematologic MRD testing, large oncology networks and an active ctDNA commercial market. The U.S. market is forecast to reach USD 3.62 billion by 2035. Canada held 3.4%, or USD 0.06 billion, while Mexico represented 1.4%, or USD 0.02 billion. Canadian access is shaped by provincial laboratory pathways; Mexican adoption is concentrated in private and tertiary cancer centers.

Europe

Europe accounted for 25.6% of 2025 revenue, equal to USD 0.43 billion, and is projected to reach USD 2.02 billion by 2035. Standardized flow-cytometry programs, cooperative hematology groups, IVDR requirements and national reimbursement structures shape adoption. Cross-country procurement favors assays with regulatory status, external quality assessment and reproducible multicenter performance.

Germany held 5.7% of global revenue, or USD 0.10 billion; the United Kingdom held 4.4%, or USD 0.07 billion; France accounted for 3.9%, or USD 0.07 billion; Italy held 2.9%, or USD 0.05 billion; and Spain represented 2.5%, or USD 0.04 billion. Nordic, Benelux and other European countries contributed the remaining 6.2%. Germany and the United Kingdom are strong molecular-testing markets, while broader European expansion depends on country-level reimbursement and laboratory consolidation.

Asia-Pacific

Asia-Pacific held 16.9% of global revenue in 2025, equal to USD 0.28 billion, and is forecast to reach USD 1.87 billion by 2035 at a 20.8% CAGR. Growth reflects expanding leukemia and myeloma treatment capacity, sequencing infrastructure and local assay development. Access remains concentrated in metropolitan academic hospitals.

China generated 5.2% of global revenue, or USD 0.09 billion, and is forecast to gain share through domestic molecular platforms and high patient volume. Japan held 4%, or USD 0.07 billion, supported by established hematology protocols and clinical research. South Korea represented 2.5%, or USD 0.04 billion, while India held 2.1%, or USD 0.04 billion. Australia, Southeast Asia and the rest of the region contributed 3.1%.

Latin America

Latin America accounted for 3.7% of global revenue in 2025, equal to USD 0.06 billion, and is projected to reach USD 0.34 billion by 2035. Flow cytometry and targeted PCR remain central in public hematology programs, while NGS and solid-tumor ctDNA use are concentrated in private centers and send-out arrangements.

Brazil represented 1.8% of global revenue, or USD 0.03 billion, and leads the region through academic hematology centers and a larger private diagnostics sector. Argentina held 0.6%, or USD 0.01 billion. Mexico is included in North America in this report. Chile, Colombia and other Latin American markets contributed 1.3%.

Middle East and Africa

The Middle East and Africa held 2% of 2025 revenue, equal to USD 0.03 billion, and is forecast to reach USD 0.26 billion by 2035. Saudi Arabia, the United Arab Emirates, Israel and South Africa contain the region’s principal advanced oncology laboratories, while broader access is limited by specialist capacity, reimbursement and sample logistics.

Saudi Arabia accounted for 0.5% of global revenue, the United Arab Emirates 0.3%, Israel 0.5% and South Africa 0.3% in 2025. Other markets made up 0.4%. Reference-laboratory partnerships and validated sample-shipping workflows offer a faster entry route than building local high-complexity capacity in every country.

Competitive Landscape

Competition spans centralized testing services, decentralized assay kits, instrumentation, sample preparation and clinical-trial partnerships. Hematologic MRD leaders benefit from validated longitudinal datasets, regulatory clearances and established reimbursement. Solid-tumor competitors differentiate through tumor-informed versus tissue-free approaches, sensitivity, tissue requirements, turnaround time, breadth of indications and published utility evidence.

The market is not won by analytical performance alone. Ordering convenience, sample-failure rate, serial result interpretation, payer support, clinical education and integration with oncology workflows determine adoption. Companies that control the pre-analytical, analytical and reporting chain can reduce variability and capture more value per patient.

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies commercializes clonoSEQ, an NGS-based assay that identifies and tracks malignant immune-receptor DNA sequences. The test is FDA-cleared for MRD assessment in multiple myeloma and B-cell acute lymphoblastic leukemia using bone marrow, and in chronic lymphocytic leukemia using blood or bone marrow. The company also offers laboratory-developed uses in additional lymphoid malignancies and sample types.

clonoSEQ’s commercial position rests on high sensitivity, standardized longitudinal tracking, Medicare coverage across several hematologic indications and extensive use in clinical research. In May 2026, Adaptive reported that clonoSEQ featured in 33 presentations across ASCO and EHA, demonstrating its embedded role in therapy studies, MRD-guided treatment-duration research and response assessment.

Natera, Inc.

Natera’s Signatera is a personalized, tumor-informed circulating tumor DNA assay used for molecular residual disease detection and recurrence monitoring across solid tumors. The workflow uses a patient’s tumor profile to select variants for serial plasma testing. Natera has built a broad evidence program in colorectal, breast, lung, bladder and other cancers, supported by oncology ordering infrastructure and CLIA-certified laboratories.

Natera is positioning MRD as a treatment-selection tool rather than prognosis alone. In July 2026, the company reported GALAXY data in resected colorectal liver metastases showing that postoperative MRD status identified patients who derived an overall-survival benefit from adjuvant chemotherapy. Its phased-variant technology and Foresight Diagnostics subsidiary expand the company’s sensitivity and biopharma capabilities.

Guardant Health, Inc.

Guardant Health markets Guardant Reveal, a tissue-free liquid-biopsy test for MRD detection and recurrence monitoring in early-stage colorectal, breast and lung cancers. The tissue-free model can simplify access where archival tumor material is limited or tissue workflow would delay testing. The company has also expanded the platform toward late-stage therapy-response monitoring.

Guardant differentiates through blood-based multiomic analysis, commercial oncology relationships and integration with a broader precision-oncology portfolio. Its evidence strategy focuses on recurrence risk, survival association and use across treatment stages. Continued adoption will depend on interventional studies, payer coverage and the ability to translate a positive result into a defined clinical action.

Invivoscribe, Inc.

Invivoscribe supplies MRD assays, reagents, software and laboratory services across hematologic malignancies. Its portfolio includes LymphoTrack clonality MRD solutions and Leukostrat assays for FLT3-ITD, NPM1 and KMT2A-related monitoring, together with NGS, digital PCR and flow-cytometry services through its LabPMM laboratory network.

The company is extending upstream into sample preparation. In September 2026, it began North American commercial shipments of PrepQuant, an automated system integrating extraction, concentration and quantification for large-volume blood, plasma and bone-marrow workflows. This positioning addresses the pre-analytical recovery problem that becomes more important as assays target lower disease levels.

Recent Developments

• September 2, 2026: Invivoscribe began North American commercial shipments of the PrepQuant System. The assay-agnostic platform integrates nucleic-acid extraction, concentration and quantification for large-volume blood, plasma and bone-marrow samples used in high-sensitivity molecular workflows.
• August 4, 2026: Invivoscribe’s LabPMM launched a global KMT2A MRD testing service to support acute-leukemia care and development programs for menin inhibitors. The service adds a specialized molecular monitoring pathway for a clinically important leukemia alteration.
• July 6, 2026: Natera reported published GALAXY study results in 298 patients with resected colorectal liver metastases. Signatera-positive patients showed an overall-survival benefit from adjuvant chemotherapy, while MRD-negative patients showed no significant survival benefit.
• May 29, 2026: Adaptive Biotechnologies announced that clonoSEQ was included in 33 presentations at ASCO and EHA 2026, covering multiple myeloma, CLL, ALL and lymphoma applications.
• May 21, 2026: Natera announced 35 ASCO studies covering Signatera, phased-variant technology and MRD-guided intervention. The program included analyses across more than 3,000 patients and 15 tumor types.

Strategic Takeaways

• Separate prognostic evidence from clinical utility. Recurrence prediction supports interest, but routine reimbursement requires proof that acting on MRD results improves outcomes or safely reduces treatment.
• Design longitudinal commercial models. The highest-value programs follow patients across baseline, treatment response and surveillance rather than selling a single test.
• Protect pre-analytical quality. Collection timing, input volume, DNA recovery and sample transport can determine sensitivity before sequencing or PCR begins.
• Match technology to disease biology. Immune-receptor sequencing, mutation tracking, flow cytometry and digital PCR solve different MRD problems; a universal workflow can weaken clinical performance.
• Build community-oncology access through reference laboratories. Electronic ordering, national logistics and payer navigation can extend advanced testing beyond academic centers.
• Standardize results across trials and countries. Biopharma sponsors need consistent assays, validated thresholds and centralized data handling to use MRD as a regulatory endpoint.
• Prioritize indications with an actionable result. Commercial adoption is strongest when a positive or negative finding maps to a defined choice involving treatment duration, escalation, transplant or surveillance.

Why Purchase the Report?

• To visualize the global minimal residual disease testing market segmentation based on type, technology, indication, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of minimal residual disease testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global minimal residual disease testing market report would provide approximately 70 tables, 63 figures, and 287 Pages.

Target Audience

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies